NRSN News & Sentiment

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NRSN

prnewswire.comDecember 23, 2024

Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study Additionally, milestone payments and double-digit royalties on annual net sales The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025 CAMBRIDGE, Mass. , Dec. 23, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NRSN

prnewswire.comDecember 18, 2024

CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NRSN

prnewswire.comDecember 11, 2024

The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS CAMBRIDGE, Mass. , Dec. 11, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NRSN

prnewswire.comNovember 21, 2024

CAMBRIDGE, Mass. , Nov. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

NRSN

prnewswire.comOctober 28, 2024

Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory decision on commercialization expected by Q1 2026 CAMBRIDGE, Mass. , Oct. 28, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NRSN

prnewswire.comOctober 15, 2024

Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenue Company aims to expand approval efforts to additional global markets CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NRSN

prnewswire.comOctober 7, 2024

CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NRSN

prnewswire.comSeptember 24, 2024

The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.